Boule Diagnostics (BOUL.ST) Stock Analysis & AI Equity Report
Boule Diagnostics (BOUL.ST) overview
Boule Diagnostics (BOUL.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Boule Diagnostics reported revenue of SEK 490m and operating profit of SEK 4.5m; the year-end share price was 4.91 SEK and market capitalisation was SEK 187m. Boule Diagnostics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Boule Diagnostics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Boule Diagnostics
Boule Diagnostics AB develops, manufactures and commercializes diagnostic instruments and consumables for blood analysis. Its Diagnostics segment provides hematology and clinical chemistry systems, reagents, controls and calibrators for human and veterinary care settings. Through OEM CDS, the company supplies custom reagents, blood controls and calibrators to other diagnostics companies worldwide.
Generate the Boule Diagnostics report
Boule Diagnostics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Boule Diagnostics and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Boule Diagnostics
Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.